Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Overview
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Impetis Biosciences Ltd
Kriya Therapeutics Inc
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
vTv Therapeutics Inc
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Drug Profiles
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokise and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Apr 23, 2021: Hua Medicine announces acceptance of a New Drug Application for Dorzagliatin in Chi - First glucokise activator (GKA) globally
Apr 13, 2021: vTv Therapeutics receives FDA breakthrough therapy desigtion for TTP399 for the treatment of type 1 diabetes
Apr 12, 2021: TTP399 SimpliciT-1 study results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
Mar 23, 2021: vTv Therapeutics announces issuance of U.S. patent covering methods of treatment using TTP399
Mar 19, 2021: Milestone development achieved in clinical trials and commercialization, Hua medicine’s dorzagliatin readying for NDA submission
Mar 18, 2021: vTv Therapeutics announces initiation of study evaluating TTP399’s potential to reduce risk of diabetic ketoacidosis in patients with type 1 diabetes
Feb 23, 2021: vTv Therapeutics announces publication in diabetes care of results from SimpliciT-1 study of TTP399 in patients with type 1 diabetes
Dec 18, 2020: Hua Medicine successfully completed the Phase III registration clinical study and announced the 52-week results of the DAWN study (HMM0302) of the combined use of dozaglietin and metformin
Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
Sep 16, 2020: vTv Therapeutics to present additiol positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combition trial of dorzagliatin
Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial
Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ?-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions
Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Hua Medicine Shanghai Ltd, 2021
Pipeline by Impetis Biosciences Ltd, 2021
Pipeline by Kriya Therapeutics Inc, 2021
Pipeline by Ligand Pharmaceuticals Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2021
Pipeline by vTv Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021